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Palmerolide A (1A) is a melanoma-inhibiting macrolide (LC50 
= 18 nM) isolated from an Antarctic tunicate collected at the NSF 
Palmer Station.
1
 Three total syntheses have been reported,
2
 as 
well as formal syntheses
3
 and several fragments.
3h–q
 Some years 
ago we planned and started a total synthesis of 1A, summarised 
in Figure 1.
4
 Unfortunately, the formation of the C15–C16 single 
bond by coupling of two C(sp
2
) carbon atoms proved to be a 
bottleneck in the process. We attempted a Negishi cross coupling
5
 
from an alkenylzinc halide (fragment C9–C15, see below, via 
Zr/Zn exchange), without success. A Stille reaction
6
 (fragment 
C9–C15, with PdCl2(NCPh)2, in DMF–THF) was likewise 
unsuccesful.
4
 In the meantime, it was reported by Nicolaou, 
Chen, et al.
2b,d,e
 that the key C15–C16 bond could be formed in a 
previous step by means of a variant of the Stille reaction, with 
AsPh3 and LiCl in NMP.
6
 In this context, we have just solved the 
problem of the C15–C16 coupling via a Negishi reaction. It may 
be of help for other difficult couplings of polyfunctional 
substrates. We also envisage to apply the procedure to the 
synthesis of palmerolide D (1D), which is the most potent 
member of the series,
1c
 in the near future. 
 
Figure 1.  Chemical structures of the main palmerolides. 
The synthesis of fragment C1–C8(9), 2, where the terminal 
methylene (C9) would be eliminated as ethene during the ring-
closing metathesis (RCM), started from a known heptynol,
7
 
which was subjected to protection, TMS removal, controlled 
reduction, TBS removal, Swern oxidation and HWE reaction 
(Scheme 1, see Supplementary Data for details). 
The synthesis of fragment C16–C23, 3, was initiated from 
the known aldol (2S,3R,5E)-3-(tert-butyldimethylsilyloxy)-6-
iodo-2,5-dimethyl-5-hexen-1-al
2b
 (see Scheme 1, last row), 
although we obtained it
4
 via a Ti enolate of N-propanoyl-1,3-
thiazolidine-2-thione,
8
 protection with TBSOTf and reduction 
with DIBALH. We converted such a 6-iodohexenal into 3 by 
Wittig reaction followed by cleavage of the O–TBS bond. The 
reaction of 2 with 3 using MNBA (the Shiina method)
9
 gave the 
desired substrate, 4, in 80% yield. 
 
Scheme 1.  Synthesis of 4 from 2 + 3 (C1–C8 + C16–C23). 
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The synthesis of fragments C(8)9–C15, where C8 would 
disappear during the RCM to link C1–C8(9) with C(8)9–C15, is 
summarised in Scheme 2. Opening of the known epoxide (2R,3S)-
1,2-epoxy-3-(4-methoxybenzyloxy)-4-pentene
10
 with a proparg-
ylic anion
11
 was followed by TMS removal, Mitsunobu inversion 
and protection of the free OH group with TBSOTf, to give 5.
4
 
From 5, we prepared stannane 6, the desired iodoalkene 7 and the 
bis(TBS)-substituted iodoalkene 8 (through a PMB-to-TBS 




Scheme 2.  Preparation of 6–8 (fragments C9–C15). 
Iodo derivative 4 was ready for the C15–C16 coupling with a 
fragment such as 6.
13
 With few further synthetic steps, a formal total 
synthesis of 1A or the first total syntheses of other palmerolides 
would have been completed.
4,13
 However, we persisted in examining 
the C15–C16 bond formation by Negishi coupling.
14
 
The fragments to be joined (either 4 + 7 or 4 + 8) are both 
expensive advanced intermediates, so that no large excess of one of 
them should be used to drive the coupling reactions to completion. 
Thus, in our trials the molar ratios between the first partner 
(alkenyl–ZnX) and the second partner (alkenyl–I) should be kept 
around 1.1–1.2 to 1.0. The positive side would be that our results 




) couplings of 
advanced synthetic intermediates. To our knowledge, relatively few 
studies aimed at finding the best ligands and conditions to perform 
state-of-the-art Negishi alkenyl–alkenyl couplings involving 
trisubstituted olefins have been published to date.
15,16
 
To find the best coupling conditions, we also had one model of 
7 and 8 (see 9, Table 1) and one model of 4 (see 10, Table 1).
17
 
Since the direct insertion of various sources of Zn into alkenyl 
iodides shown in Table 1 (even in DMA or DMF at 80 ºC)
18
 did 
not work, we attempted the procedure reported by Knochel et al.
19
 
(addition of LiCl), which is so useful for RX and many ArX, but it 
did not work with our iodides in refluxing THF.
20
 Thus, we were 
forced to revisit classical lithiation reactions with t-BuLi, followed 
by Li-to-Zn exchange with ZnX2.
21
 ZnCl2 and ZnBr2 gave 
identical results, provided that the samples were anhydrous.
15,16,21
 
We preferred ZnBr2, however, as it is less hygroscopic. 
Table 1 summarises around 90 trials (most of them 
unsuccessful) in which many representative catalysts, such as 
Pd(PPh3)4, Pd2dba3/Xantphos, Pd2dba3/DPEphos, Pd2dba3/XPhos 
and Pd2dba3/RuPhos, were compared.
22
 The standard Pd(PPh3)4 
gave rise to full consumption of the second partner only on 
heating (compare entries 1–4); addition of one further equiv of t-
BuLi was not relevant. On the other hand, the bidentate ligand-
containing solutions (entries 5–7) were capable of completing 
the reaction of 9 with 10 (to give 11) in 4 h hours at RT. 
Xantphos and DPEphos gave similar excellent results, so we 
used them indistinctly. In these experiments at RT, a crucial step 
 
 
was to solve (to "activate") the catalyst by heating the 
suspension of Pd2dba3
23
 in THF, under Ar, for few seconds with 
the diphosphine or biphenylphosphine, until clear solutions were 
obtained.
24
 These were yellowish green in the cases of Xantphos 
and Ruphos, yellow with DPEphos and reddish orange with 
XPhos. Without this previous activation, the combination of these 
phosphines with Pd2(dba)3 showed no advantage over Pd(PPh3)4. 
On the other hand, biphenylphosphines plus Pd2(dba)3 
(entries 8 and 9) were less active, even after such a previous 
activation. However, when the Pd
0
–XPhos complex was 
generated from o-palladacycle [PdCl(NH2CH2CH2C6H4)XPhos] 
(XPhos-Pd-G1) and from 2-NH2-2'-[Pd(OMs)XPhos]biphenyl 
(XPhos-Pd-G3),
25
 conversions improved (up to 70% after 6 h, 




Optimisation of Ligands and Conditions for the Coupling of 
Iodoalkenes 7–9 with 10 
 
Entry RI Coupling conditionsa Diene, %b 
1 9 1% Pd(PPh3)4, RT, 16 h 11, 70 
2 9 2% Pd(PPh3)4, RT, 4 h 11, 50 
3 9 2% Pd(PPh3)4, RT, 4 h (+t-BuLi) 11, 50 
4 9 5% Pd(PPh3)4, 60 ºC, 4 h 11, 85 
5 9 1% Pd2dba3, 2.5% Xantphos,
c RT, 4 h 11, 88 
6 9 1% Pd2dba3·CHCl3, 2.5% Xantphos,
c RT, 4 
h 
11, 87 
7 9 1% Pd2dba3, 2.5% DPEphos,
c RT, 4 h 11, 88 
8 9 1% Pd2dba3, 3% XPhos,
c RT, 6 h 11, 25d 
9 9 1% Pd2dba3, 3% RuPhos,
c RT, 6 h 11, 30d 
10 9 2% XPhos-Pd-G1, RT, 6 h 11, 70d 
11 9 2% XPhos-Pd-G3, RT, 6 h 11, 70d,e 
12 7 5% Pd2dba3, 12% Xantphos, 60 ºC, 16 h         0
d 
13 7 5% Pd2dba3, 12% Xantphos, 60 ºC, 16 h (+t-BuLi)         0
d 
14 8 5% Pd2dba3, 12% Xantphos, 60 ºC, 16 h         0
d 
15 8 5% Pd2dba3, 12% Xantphos, 60 ºC, 16 h (+t-BuLi) 12, 78 
a At 0.2 M concentrations. Catalyst/reagent percentages in mol %. All 
reactions under Ar, with 110 mol % of the first alkenyl iodide, 120 mol % of 
anhydrous ZnBr2 (or ZnCl2) and 210–220 mol % of t-BuLi unless otherwise 
indicated (as "+t-BuLi", where 330 mol % of t-BuLi was added), referred to the 
second iodoalkene, 10. 
b Conversions (by NMR) or, in bold red, isolated yields after flash column 
chromatography (when conversions were 100%). 
c The wine-red suspension of Pd2dba3 in THF plus the phosphine was heated 
for few seconds until a solution was obtained. After cooling to RT, the PdLn 
solution was added via cannula to the reaction flask (all under Ar). Without this 
ligand exchange the reaction rates were much slower. Colour did not change 
with 2-(di-tert-butylphosphino)-2',4',6'-triisopropyl-3,6-dimethoxybiphenyl, t-
BuBrettPhos; the mixture was inefficient at RT. 
d Part or all of 10 was recovered unchanged; the de-iodinated alkenes from 
7–9 were also isolated. 
e This experiment was performed with pre-activation of the catalyst (XPhos-
Pd-G3 + RCH=CHZnX for 30 s at 60 ºC, orange-to-brown colour change), 




Compounds 7 and 8 did not react with 10 under the best 
conditions up to this point, with 2.2 equiv of t-BuLi, even with 
more catalyst, even on heating (see entries 12 and 14). Use of 3 
equiv of t-BuLi, which Smith et al.
16a










 had no effect in the case of 7 (entry 13), whereas 8 
did react (entry 15, 100% conversion, 78% isolated yield of 12).
26
 
Thus, the presence of PMBO groups (and presumably of other 
coordinating and/or prone to be lithiated PGs) is contraindicated. 
Moreover, for substrates with silyloxy groups, 3.3 equiv of t-BuLi 
are essential. The addition of 200 mol % of LiBr to the alkenylzinc 
halide, as an alternative to the use of 3.3 equiv of t-BuLi, so useful 
in other couplings,
27
 did not help in our case. 
We finally undertook the coupling of the organozinc halide 
from 8 with 4 (Scheme 3) using the optimised conditions shown 
in entry 15. To our delight, the conversion was complete. After 
flash column chromatography and preparative TLC, compound 
13 was isolated in 74% yield (not optimised). 
 
Scheme 3.  Negishi cross-coupling reaction of 8 with 4. 
 
In conclusion, with the goal of obtaining samples of palmerolides 
to check their mechanism(s) of action, we first improved the 
difficult C15–C16 Negishi coupling using model compounds. The 
pre-activated Pd–Xantphos complex ("active" yellowish green 
solution) and the pre-activated Pd–DPEphos complex ("active" 
yellow solution) turned out to be the most efficient catalysts. In 
other words, several excellent catalysts and procedures for other 
cross couplings did not work so efficiently in the present case. 
Excess t-BuLi and suitable PGs (silyl groups but not PMB) are also 
essential when the zincates or organozinc halides to be coupled 
contain oxygen functional groups. We plan to synthesise again 13 
(and analogues with two different silyl PGs, if necessary) in 
sufficient amounts to attempt a synthesis of 1D and analogues 
relying on this optimised procedure. 
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